secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0000950170-25-097323
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes reports positive phase 2 results for alixorexton in narcolepsy type 1; primary endpoint met
--------------------------------------------------------------------------------

- Alixorexton met primary endpoint: statistically significant and dose-dependent improvements in wakefulness (MWT) vs placebo (p<0.0001 at all doses).
- Key secondary: ESS improved significantly at all doses (p<0.0001); weekly cataplexy rates numerically improved, significant at 6 mg (p=0.005).
- Exploratory endpoints: alixorexton improved disease severity (NSS), cognition (BC-CCI), and fatigue (PROMIS-Fatigue) at all doses (p<0.01).
- Alixorexton was generally well tolerated; no serious AEs; >95% of patients entered open-label extension.
- Data support rapid initiation of global phase 3 program in NT1; detailed results at World Sleep Congress Sept 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025097323/0000950170-25-097323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000095017025097323/alks-20250721.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-097323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer